{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"41.1","upperLimit":"80.0","value":"60.1"},{"groupId":"OG001","lowerLimit":"16.1","upperLimit":"21.1","value":"20.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"176"}],"units":"Participants"}],"description":"Time to progression (TTP) was calculated as the time from randomization to the first documentation of progressive disease based on the myeloma response determination criteria developed by Bladé et. al., Br J Haematol 1998; 102:1115-1123.","dispersionType":"95% Confidence Interval","groups":[{"description":"CC-5013 (lenalidomide) plus oral high-dose dexamethasone","id":"OG000","title":"CC-5013/Dex"},{"description":"Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone","id":"OG001","title":"Placebo/Dex"}],"paramType":"MEDIAN","populationDescription":"Analysis conducted on the Intent-To-Treat (ITT) Population. The ITT Population was defined as all subjects randomized.","reportingStatus":"POSTED","timeFrame":"60 weeks (median Time To Progression of CC-5013/Dex treatment group)","title":"Time to Tumor Progression (TTP)","type":"PRIMARY","unitOfMeasure":"Weeks"}